PLIANT THERAPEUTICS INC (PLRX) Earnings History & Surprises
NASDAQ:PLRX • US7291391057
1.33 USD
+0.04 (+3.1%)
Last: Mar 6, 2026, 08:00 PM
Past quarterly earnings results for PLIANT THERAPEUTICS INC (PLRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.41
Revenue Estimate
Last Reported
Release DateMar 2, 2026
PeriodQ3 / 2025
EPS Reported-$0.43
EPS Surprise 19.51%
Revenue Surprise %
Beat Rate
31%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.43 | -0.53 | 19.51% | 54.74% | - | - | ||
| Q2 2025 | -0.71 | -0.71 | -0.10% | 22.83% | - | - | ||
| Q1 2025 | -0.92 | -0.74 | -24.53% | -17.95% | - | - | ||
| Q4 2024 | -0.82 | -1.00 | 18.20% | -18.84% | - | - | ||
| Q3 2024 | -0.95 | -0.99 | 3.90% | -35.71% | 541.875K | -100.00% | - | |
| Q2 2024 | -0.92 | -0.87 | -6.32% | -31.43% | 498.097K | -100.00% | -100.00% | |
| Q1 2024 | -0.78 | -0.79 | 0.89% | -16.42% | 473.79K | -100.00% | -100.00% | |
| Q4 2023 | -0.69 | -0.83 | 16.88% | 4.17% | 510K | -100.00% | -100.00% | |
| Q3 2023 | -0.70 | -0.79 | 11.45% | -7.69% | 765K | -100.00% | -100.00% | |
| Q2 2023 | -0.70 | -0.73 | 3.79% | 14.63% | 248K | 899.456K | -72.43% | -95.03% |
| Q1 2023 | -0.67 | -0.68 | 1.72% | 14.10% | 1.332M | 1.239M | 7.51% | 6.56% |
| Q4 2022 | -0.72 | -0.71 | -0.83% | -5.73% | 1.97M | 1.459M | 35.02% | -1.50% |
| Q3 2022 | -0.65 | -0.76 | 14.02% | 13.33% | 1.48M | 1.625M | -8.92% | -8.07% |
| Q2 2022 | -0.82 | -0.83 | 1.02% | -28.12% | 4.99M | 1.224M | 307.68% | 178.77% |
| Q1 2022 | -0.78 | -0.77 | -1.96% | -21.88% | 1.25M | 1.071M | 16.71% | -42.40% |
| Q4 2021 | -0.68 | -0.78 | 12.15% | -26.11% | 2M | 2.55M | -21.57% | -55.26% |
| Q3 2021 | -0.75 | -0.70 | -6.56% | -59.57% | 1.61M | 2.423M | -33.55% | -66.53% |
| Q2 2021 | -0.64 | -0.68 | 6.29% | 53.96% | 1.79M | 3.188M | -43.85% | -50.28% |
| Q1 2021 | -0.64 | -0.62 | -3.88% | - | 2.17M | 3.239M | -33.00% | -92.50% |
| Q4 2020 | -0.54 | -0.73 | 25.70% | - | 4.47M | 3.434M | 30.17% | - |
| Q3 2020 | -0.47 | -0.87 | 45.69% | - | 4.81M | 2.55M | 88.63% | - |
| Q2 2020 | -1.39 | -0.79 | -76.24% | - | 3.6M | 2.55M | 41.18% | - |
| Q1 2020 | - | - | 28.94M | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-0.63%
Max EPS beat (4)
18.20%
Min EPS beat (4)
-24.53%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, PLRX has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, PLRX reported -0.6% below the EPS estimates on average.
PLIANT THERAPEUTICS INC / PLRX Earnings FAQ
When did PLIANT THERAPEUTICS INC (PLRX) report earnings last quarter?
PLIANT THERAPEUTICS INC (PLRX) last reported earnings on 3/2/2026.
Can you provide information on whether PLIANT THERAPEUTICS INC beat earnings estimates in the last quarter?
PLIANT THERAPEUTICS INC (PLRX) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does PLRX stock beat earnings estimates?
In the last 4 quarters, PLIANT THERAPEUTICS INC (PLRX) has beaten EPS estimates in 2 out of 4 releases.